Jochen H. Lorch
Elite in Thyroid Cancer

Dr. Jochen H. Lorch

Hematology | Oncology
Northwestern Medical Group
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
Offers Telehealth
32 Years of Experience
Elite in Thyroid Cancer
Northwestern Medical Group
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jochen Lorch is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Lorch has been practicing medicine for over 32 years and is rated as an Elite provider by MediFind in the treatment of Thyroid Cancer. His top areas of expertise are Anaplastic Thyroid Cancer, Thyroid Cancer, Medullary Thyroid Carcinoma, Adenoid Cystic Carcinoma, and Thyroidectomy.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 28 articles and participated in 7 clinical trials in the study of Thyroid Cancer.

Graduate Institution
University Of Regensburg, 1994.0
Residency
University of Pennsylvania Health System
Specialties
Hematology
Oncology
Licenses
Internal Medicine in MA
Board Certifications
American Board Of Internal Medicine - Medical Oncology (Certified)
Fellowships
McGaw Medical Center of Northwestern University
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Palos Community Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 8 Less Insurance Carriers -

Locations

675 N St Clair St Ste 21-100, Galter Pavilion, Chicago, IL 60611
Call: 866-587-4322

Additional Areas of Focus

Dr. Lorch has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Radiation, Procedure, Biological, Drug
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer
A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck
A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug, Radiation
Study Drugs: Buparlisib, Cisplatin
Study Phase: Phase 1
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drug: MLN0128
Study Phase: Phase 1/Phase 2
A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients
A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients
Enrollment Status: Completed
Publish Date: January 11, 2024
Intervention Type: Drug
Study Drug: DPX-E7 vaccine
Study Phase: Phase 1/Phase 2
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Biological
Study Drug: Epstein-Barr Virus Specific Immunotherapy
Study Phase: Phase 2
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Enrollment Status: Completed
Publish Date: October 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

92 Total Publications

33 Unresolved Questions in Nanoscience and Nanotechnology.
33 Unresolved Questions in Nanoscience and Nanotechnology.
Journal: ACS nano
Published: September 04, 2025
View All 92 Publications
Similar Doctors
Young K. Chae
Advanced in Thyroid Cancer
Dr. Young K. Chae
Hematology | Oncology
Advanced in Thyroid Cancer
Dr. Young K. Chae
Hematology | Oncology
233 E Superior St 1st Fl, Olson Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
24+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Young Chae is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Chae has been practicing medicine for over 24 years and is rated as an Elite provider by MediFind in the treatment of Thyroid Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

Advanced in Thyroid Cancer
Dr. Patricia A. Robinson
Hematology | Oncology
Advanced in Thyroid Cancer
Dr. Patricia A. Robinson
Hematology | Oncology
250 E Superior St Ste 4-420, Prentice Women's Hospital, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
30+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Patricia Robinson is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Robinson has been practicing medicine for over 30 years and is rated as a Distinguished provider by MediFind in the treatment of Thyroid Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, Endoscopy, and Ureteroscopy.

Veerpal Singh
Advanced in Thyroid Cancer
Dr. Veerpal Singh
Hematology | Oncology
Advanced in Thyroid Cancer
Dr. Veerpal Singh
Hematology | Oncology

Illinois Cancer Specialists

1710 N Randall Rd, 
Elgin, IL 
 (39.2 miles away)
847-931-0909
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Veerpal Singh is a Hematologist and an Oncologist in Elgin, Illinois. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Thyroid Cancer. His top areas of expertise are Gallbladder Cancer, Lynch Syndrome, Colorectal Cancer, Gallbladder Adenocarcinoma, and Bone Marrow Aspiration.

VIEW MORE THYROID CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lorch's expertise for a condition
ConditionClose
  • Elite
  • Anaplastic Thyroid Cancer
    Dr. Lorch is
    Elite
    . Learn about Anaplastic Thyroid Cancer.
    See more Anaplastic Thyroid Cancer experts
  • Medullary Thyroid Carcinoma
    Dr. Lorch is
    Elite
    . Learn about Medullary Thyroid Carcinoma.
    See more Medullary Thyroid Carcinoma experts
  • Thyroid Cancer
    Dr. Lorch is
    Elite
    . Learn about Thyroid Cancer.
    See more Thyroid Cancer experts
  • Distinguished
  • Acinic Cell Carcinoma of Salivary Glands
    Dr. Lorch is
    Distinguished
    . Learn about Acinic Cell Carcinoma of Salivary Glands.
    See more Acinic Cell Carcinoma of Salivary Glands experts
  • Adenoid Cystic Carcinoma
    Dr. Lorch is
    Distinguished
    . Learn about Adenoid Cystic Carcinoma.
    See more Adenoid Cystic Carcinoma experts
  • Epithelial-Myoepithelial Carcinoma
    Dr. Lorch is
    Distinguished
    . Learn about Epithelial-Myoepithelial Carcinoma.
    See more Epithelial-Myoepithelial Carcinoma experts
  • Follicular Thyroid Cancer
    Dr. Lorch is
    Distinguished
    . Learn about Follicular Thyroid Cancer.
    See more Follicular Thyroid Cancer experts
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
    Dr. Lorch is
    Distinguished
    . Learn about Head and Neck Squamous Cell Carcinoma (HNSCC).
    See more Head and Neck Squamous Cell Carcinoma (HNSCC) experts
  • Nasopharyngeal Carcinoma
    Dr. Lorch is
    Distinguished
    . Learn about Nasopharyngeal Carcinoma.
    See more Nasopharyngeal Carcinoma experts
View All 10 Distinguished Conditions
  • Advanced
  • Glioma
    Dr. Lorch is
    Advanced
    . Learn about Glioma.
    See more Glioma experts
  • Lacrimal Gland Tumor
    Dr. Lorch is
    Advanced
    . Learn about Lacrimal Gland Tumor.
    See more Lacrimal Gland Tumor experts
  • Laryngeal Cancer
    Dr. Lorch is
    Advanced
    . Learn about Laryngeal Cancer.
    See more Laryngeal Cancer experts
  • Merkel Cell Carcinoma
    Dr. Lorch is
    Advanced
    . Learn about Merkel Cell Carcinoma.
    See more Merkel Cell Carcinoma experts
  • Oral Squamous Cell Carcinoma
    Dr. Lorch is
    Advanced
    . Learn about Oral Squamous Cell Carcinoma.
    See more Oral Squamous Cell Carcinoma experts
  • Throat Cancer
    Dr. Lorch is
    Advanced
    . Learn about Throat Cancer.
    See more Throat Cancer experts
  • Experienced
  • Bone Tumor
    Dr. Lorch is
    Experienced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Colorectal Cancer
    Dr. Lorch is
    Experienced
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Ewing Sarcoma
    Dr. Lorch is
    Experienced
    . Learn about Ewing Sarcoma.
    See more Ewing Sarcoma experts
  • Lung Cancer
    Dr. Lorch is
    Experienced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Melanoma
    Dr. Lorch is
    Experienced
    . Learn about Melanoma.
    See more Melanoma experts
  • Melanoma of the Eye
    Dr. Lorch is
    Experienced
    . Learn about Melanoma of the Eye.
    See more Melanoma of the Eye experts
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.